Skip Navigation

European Journal of Heart Failure 2006 8(3):321-325; doi:10.1016/j.ejheart.2005.08.006
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (11)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Ingle, L.
Right arrow Articles by Cleland, J.G.F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ingle, L.
Right arrow Articles by Cleland, J.G.F.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2005 European Society of Cardiology

Clinical determinants of poor six-minute walk test performance in patients with left ventricular systolic dysfunction and no major structural heart disease

L. Ingle*, A.S. Rigby, S. Nabb, P.K. Jones, A.L. Clark and J.G.F. Cleland

Department of Cardiology, Castle Hill Hospital Castle Road, Cottingham, Hull, HU16 5JQ, UK

* Corresponding author. Tel.: +44 148 262 3732; fax: +44 148 262 4071. E-mail address: L.Ingle{at}hull.ac.uk


   Abstract

Background: The clinical determinants of six-minute walk test (6-MWT) performance in patients with left ventricular systolic dysfunction (LVSD) have rarely been investigated, and it is not clear whether they differ from patients referred for the assessment of symptoms of heart failure who do not have major structural heart disease (MSHD).

Methods and Results: 571 patients with LVSD enrolled in a chronic disease management programme (79% male; mean age 71±10 years; BMI 28±5) completed a 6-MWT with a mean distance 337±103 m. 688 patients referred with suspected heart failure but in whom MSHD was excluded (49% male; mean age 70±11 years; BMI 28±6) had a mean 6-MWT distance of 391±106 m (P<0.001 compared to patients with LVSD). Relationships with walking distance were determined by calculating odds ratios (ORs) with 95% confidence intervals (CIs) for walking ≤300 versus >300 m. In patients with LVSD, predictors of poor walking distance (≤300 m) included age ≥75 years (OR=4.0, 95% CI=2.4–6.4); low BMI (<20) (OR=3.4, 95% CI=1.6–7.3); anaemia (OR=2.8, 95% CI=1.8–4.2); resting heart rate >80 beats min–1 (OR=2.2, 95% CI=1.3–3.5); and being female (OR=2.0, 95% CI=1.3–3.0). Serum creatinine and NT-proBNP showed dose–response effects, as did self-perceived feelings of depression and anxiety. Determinants of 6-MWT in patients without MSHD were similar including age ≥75 years (OR=6.0, 95% CI=3.4–10.4), anaemia (OR=2.8, 95% CI=1.6–4.9), resting HR >80 beats min–1 (OR=2.5, 95% CI=1.4–4.4) and being female (OR=1.6, 95% CI=1.9–2.4). NT-proBNP and self-perceived feelings of depression and anxiety also showed dose–response effects.

Conclusion: The determinants of poor 6-MWT performance depend on physical–cardiovascular and non-cardiovascular, and psychological factors. Clinical predictors for poor walking performance are similar for patients with LVSD and without MSHD.

Key Words: Clinical determinants • Poor 6-MWT performance • LVSD • No MSHD

Received April 5, 2005; Revised July 20, 2005; Accepted August 25, 2005


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
Eur J Heart FailHome page
J. T. Parissis, D. Farmakis, M. Nikolaou, D. Birmpa, V. Bistola, I. Paraskevaidis, I. Ikonomidis, S. Gaitani, K. Venetsanou, G. Filippatos, et al.
Plasma B-type natriuretic peptide and anti-inflammatory cytokine interleukin-10 levels predict adverse clinical outcome in chronic heart failure patients with depressive symptoms: a 1-year follow-up study
Eur J Heart Fail, October 1, 2009; 11(10): 967 - 972.
[Abstract] [Full Text] [PDF]


Home page
HeartHome page
J T Parissis, M Nikolaou, D Farmakis, V Bistola, I A Paraskevaidis, S Adamopoulos, G Filippatos, and D T Kremastinos
Clinical and prognostic implications of self-rating depression scales and plasma B-type natriuretic peptide in hospitalised patients with chronic heart failure
Heart, May 1, 2008; 94(5): 585 - 589.
[Abstract] [Full Text] [PDF]


Home page
Eur J Heart FailHome page
M. Metra, P. Ponikowski, K. Dickstein, J. J.V. McMurray, A. Gavazzi, C.-H. Bergh, A. G. Fraser, T. Jaarsma, A. Pitsis, P. Mohacsi, et al.
Advanced chronic heart failure: A position statement from the Study Group on Advanced Heart Failure of the Heart Failure Association of the European Society of Cardiology
Eur J Heart Fail, June 1, 2007; 9(6-7): 684 - 694.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart JHome page
L. Ingle, A. S. Rigby, S. Carroll, R. Butterly, R. F. King, C. B. Cooke, J. G.J.F. Cleland, and A. L. Clark
Prognostic value of the 6 min walk test and self-perceived symptom severity in older patients with chronic heart failure
Eur. Heart J., March 1, 2007; 28(5): 560 - 568.
[Abstract] [Full Text] [PDF]



Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.